Schellens JH - Search Results

1

Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors.

Stuurman FE, Voest EE, Awada A, Witteveen PO, Bergeland T, Hals PA, Rasch W, Schellens JH, Hendlisz A. Stuurman FE, et al. Among authors: schellens jh. Invest New Drugs. 2013 Aug;31(4):959-66. doi: 10.1007/s10637-013-9925-z. Epub 2013 Jan 24. Invest New Drugs. 2013. PMID: 23345000 Clinical Trial.

2

A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.

Planting A, Kho S, van der Burg M, Goey H, Schellens J, van den Bent M, van der Gaast A, de Boer-Dennert M, Stoter G, Verweij J. Planting A, et al. Cancer Chemother Pharmacol. 1997;40(4):347-52. doi: 10.1007/s002800050668. Cancer Chemother Pharmacol. 1997. PMID: 9225954 Free article. Clinical Trial.

3

Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study.

Schoemaker NE, Herben VM, de Jong LA, van Waardenburg RC, Pluim D, ten Bokkel Huinink WW, Beijnen JH, Schellens JH. Schoemaker NE, et al. Among authors: schellens jh. Anticancer Drugs. 2002 Jan;13(1):87-91. doi: 10.1097/00001813-200201000-00010. Anticancer Drugs. 2002. PMID: 11914645

4

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.

van Kesteren C, Twelves C, Bowman A, Hoekman K, López-Lázaro L, Jimeno J, Guzman C, Mathôt RA, Simpson A, Vermorken JB, Smyth J, Schellens JH, Hillebrand MJ, Rosing H, Beijnen JH. van Kesteren C, et al. Among authors: schellens jh. Anticancer Drugs. 2002 Apr;13(4):381-93. doi: 10.1097/00001813-200204000-00007. Anticancer Drugs. 2002. PMID: 11984084 Clinical Trial.

5

Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors.

Crul M, de Klerk GJ, Swart M, Weiner L, Palmer PA, Bol CJ, Beijnen JH, Schellens JH. Crul M, et al. Among authors: schellens jh. Eur J Drug Metab Pharmacokinet. 2002 Jan-Mar;27(1):61-5. doi: 10.1007/BF03190407. Eur J Drug Metab Pharmacokinet. 2002. PMID: 11996329 Clinical Trial.

6

Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.

Schellens JH, Heinrich B, Lehnert M, Gore ME, Kaye SB, Dombernowsky P, Paridaens R, van Oosterom AT, Verweij J, Loos WJ, Calvert H, Pavlidis N, Cortes-Funes H, Wanders J, Roelvink M, Sessa C, Selinger K, Wissel PS, Gamucci T, Hanauske AR. Schellens JH, et al. Invest New Drugs. 2002 Feb;20(1):83-93. doi: 10.1023/a:1014454821885. Invest New Drugs. 2002. PMID: 12003197 Clinical Trial.

7

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.

Crul M, de Klerk GJ, Swart M, van't Veer LJ, de Jong D, Boerrigter L, Palmer PA, Bol CJ, Tan H, de Gast GC, Beijnen JH, Schellens JH. Crul M, et al. Among authors: schellens jh. J Clin Oncol. 2002 Jun 1;20(11):2726-35. doi: 10.1200/JCO.2002.09.116. J Clin Oncol. 2002. PMID: 12039935 Clinical Trial.

8

Urinary and fecal excretion of topotecan in patients with malignant solid tumours.

Herben VM, Schoemaker nE, Rosing H, van Zomeren DM, ten Bokkel Huinink WW, Dubbelman R, Hearn S, Schellens JH, Beijnen JH. Herben VM, et al. Among authors: schellens jh. Cancer Chemother Pharmacol. 2002 Jul;50(1):59-64. doi: 10.1007/s00280-002-0454-2. Epub 2002 Apr 5. Cancer Chemother Pharmacol. 2002. PMID: 12111113 Clinical Trial.

9

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.

Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser M, Reichert S, Knebel NG, Schellens JH, Beijnen JH, ten Bokkel Huinink WW. Crul M, et al. Among authors: schellens jh. Eur J Cancer. 2002 Aug;38(12):1615-21. doi: 10.1016/s0959-8049(02)00127-2. Eur J Cancer. 2002. PMID: 12142051 Clinical Trial.

10

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin.

Schoemaker NE, van Kesteren C, Rosing H, Jansen S, Swart M, Lieverst J, Fraier D, Breda M, Pellizzoni C, Spinelli R, Grazia Porro M, Beijnen JH, Schellens JH, ten Bokkel Huinink WW. Schoemaker NE, et al. Among authors: schellens jh. Br J Cancer. 2002 Sep 9;87(6):608-14. doi: 10.1038/sj.bjc.6600516. Br J Cancer. 2002. PMID: 12237769 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

890 results

Search Page